Core Viewpoint - CAMP4 Therapeutics has appointed Michael MacLean to its Board of Directors to enhance its strategic and financial leadership as it advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder [1][2] Group 1: Appointment and Expertise - Michael MacLean brings over 35 years of strategic financial leadership in biotechnology and life sciences, with experience in guiding biotech companies through critical growth phases [2] - His previous roles include Chief Financial Officer at Avidity Biosciences, where he led finance until its acquisition by Novartis in 2026, and Chief Financial Officer at Akcea Therapeutics [2] - MacLean expressed enthusiasm about joining CAMP4 at a pivotal moment, emphasizing the importance of the company's work with its regRNA-targeting platform [2] Group 2: Company Overview - CAMP4 Therapeutics is focused on developing disease-modifying treatments for genetic diseases by amplifying healthy protein levels [4] - The company utilizes a proprietary RAP Platform® to map regulatory RNAs (regRNAs) and generate therapeutic candidates targeting genes associated with over 1,200 disorders [4] - The goal is to provide clinically meaningful increases in protein expression for conditions where current treatment options are limited [4]

Summary of Camp4 Therapeutics Conference Call Company Overview - **Company**: Camp4 Therapeutics (NasdaqGM:CAMP) - **Event**: Global Healthcare Conference of Leerink Partners, March 09, 2026 Technology Platform - **Core Technology**: Utilizes antisense oligonucleotides (ASOs) to increase gene expression, targeting regulatory RNAs from the non-coding genome, specifically enhancers and promoters [4][5] - **Differentiation**: Unlike traditional oligonucleotide therapies that focus on downregulation, Camp4's approach allows for precise upregulation of gene expression, particularly in haploinsufficient conditions [4][5][10] - **Targeting Mechanism**: The platform catalogs regulatory RNAs and their corresponding genes in various cell types, enabling targeted drug development [4] Clinical Focus - **Haploinsufficient Diseases**: The company focuses on diseases where patients are missing 50% of necessary gene expression, aiming for a twofold increase in expression as the ideal target [10][11] - **Current Programs**: Shifted focus from urea cycle disorder (UCD) to the SYNGAP1 program due to higher conviction in clinical success and significant unmet medical need [19][21] - **SYNGAP1 Disease**: A haploinsufficient condition with no approved treatments, characterized by cognitive impairment, seizures, and mobility issues [27][28] Clinical Development Strategy - **Target Population**: Aiming to treat children diagnosed with SYNGAP1 as early as age 2 or 3, leveraging advancements in genetic testing for quicker diagnosis [39][41] - **Dosing Strategy**: Plans to initiate with multiple ascending dose (MAD) studies directly, based on regulatory feedback and the high unmet need of the patient population [49][50] - **Endpoints**: Focus on various clinical endpoints including seizure frequency, cognitive assessments, and overall quality of life metrics [61][63] Preclinical Data - **Efficacy**: Demonstrated ability to reverse disease symptoms in preclinical models, including humanized mice and primates, with a consistent twofold increase in protein expression [64][66] - **Safety**: No safety issues reported in preclinical studies, reinforcing confidence in the therapeutic approach [22][66] Collaboration and Future Opportunities - **GSK Collaboration**: Engaged in a partnership with GSK to explore additional therapeutic indications, with a focus on CNS and kidney diseases [85][87] - **Pipeline Expansion**: Plans to develop additional programs targeting similar haploinsufficient conditions, with potential for significant market opportunities [90][91] Key Takeaways - **Market Potential**: The SYNGAP1 program is viewed as a multi-billion dollar opportunity, with the potential to unlock further value for the platform as additional programs are developed [94] - **Regulatory Engagement**: Ongoing discussions with regulatory agencies are positive, indicating familiarity and comfort with the technology, which may expedite clinical development [82][83] This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Camp4 Therapeutics in addressing significant unmet medical needs through their unique technology platform and strategic clinical focus.

Core Insights - CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics aimed at treating genetic diseases by restoring healthy protein levels [1][3] - The company has granted a non-qualified stock option for 80,000 shares to a new employee as an inducement for joining the company [1][2] Stock Option Details - The stock option has a ten-year term with an exercise price of $4.39, equal to the closing price on the grant date [2] - The option will vest over four years, with 25% vesting on the one-year anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on continued service [2] Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases, utilizing a proprietary RAP Platform to amplify mRNA and target regulatory RNAs [3] - The therapeutic approach focuses on amplifying healthy protein expression, which may provide significant clinical benefits for conditions characterized by haploinsufficiency and recessive partial loss-of-function disorders [3]